Discounted Cash Flow (DCF) Analysis Levered
Altimmune, Inc. (ALT)
$13.23
-0.68 (-4.89%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 10.74 | 10.33 | 5.80 | 8.19 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -20.21 | -9.39 | -9.60 | -34.44 | -0.01 | -0.01 | -0.01 | -0 | -0 | -0 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.17 | -1.02 | -0.03 | -0.34 | -0 | -0 | -0 | -0 | -0 | -0 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -20.38 | -10.40 | -9.63 | -34.78 | -0.01 | -0.01 | -0.01 | -0 | -0 | -0 |
Weighted Average Cost Of Capital
| Share price | $ 13.23 |
|---|---|
| Beta | 0.190 |
| Diluted Shares Outstanding | 25.64 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 5.00% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 4.415 |
| Total Debt | - |
| Total Equity | 339.18 |
| Total Capital | 339.18 |
| Debt Weighting | 0.00 |
| Equity Weighting | 100.00 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 10.74 | 10.33 | 5.80 | 8.19 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.21 | -9.39 | -9.60 | -34.44 | -0.01 | -0.01 | -0.01 | -0 | -0 | -0 |
| Capital Expenditure | -0.17 | -1.02 | -0.03 | -0.34 | -0 | -0 | -0 | -0 | -0 | -0 |
| Free Cash Flow | -20.38 | -10.40 | -9.63 | -34.78 | -0.01 | -0.01 | -0.01 | -0 | -0 | -0 |
| WACC | ||||||||||
| PV LFCF | -0.01 | -0 | -0 | -0 | -0 | |||||
| SUM PV LFCF | -0.02 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 4.42 |
| Free cash flow (t + 1) | -0 |
| Terminal Value | -0.09 |
| Present Value of Terminal Value | -0.07 |
Intrinsic Value
| Enterprise Value | -0.09 |
|---|---|
| Net Debt | -190.30 |
| Equity Value | 190.21 |
| Shares Outstanding | 25.64 |
| Equity Value Per Share | 7.42 |